Skip to content

Ginkgo Bioworks DNA Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Charles River Laboratories logo
Charles River LaboratoriesCRL
Azenta logo
AzentaAZTA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's preferred stock, shares authorized?
Ginkgo Bioworks (DNA) reported preferred stock, shares authorized of $200M in Q1 2026.
How has Ginkgo Bioworks's preferred stock, shares authorized changed year-over-year?
Ginkgo Bioworks's preferred stock, shares authorized decreased by 0.0% year-over-year, from $200M to $200M.
What is the long-term trend for Ginkgo Bioworks's preferred stock, shares authorized?
Over 5 years (2020 to 2025), Ginkgo Bioworks's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $200M to $200M.